For the Inventor, By the Inventor

Enter assignee name

Seoul, South Korea

Novmetapharma Co., Ltd.

Calculating rank

USPTO Granted Patents = 15

EPO Patents = 9

Forward Citations = 11

Loading Chart...

Loading Chart...

35 inventors (with patents filed for the assignee):

Heon Jong Lee (7 out of 9 patents)

Hoe Yune Jung (7 out of 10 patents)

Hoe-Yune Jung (5 out of 5 patents)

4. In-Kyu Lee (3 out of 7 patents)

5. Jae-Han Jeon (3 out of 7 patents)

6. Heon-Jong Lee (3 out of 3 patents)

7. Jong-Su Jeon (3 out of 3 patents)

8. Yon-Su Kim (3 out of 3 patents)

9. Seung-Hee Yang (3 out of 3 patents)

10. Yong-Chul Kim (3 out of 26 patents)

11. Jong-Joo Moon (3 out of 3 patents)

12. Hwan-Soo Yoo (3 out of 3 patents)

13. Kyeong-Mi Choi (3 out of 3 patents)

14. Do Hyun Lee (3 out of 4 patents)

15. Kay Olmstead (2 out of 19 patents)

15 patents: Sort by Forward Citations

1. 12496309 - METHOD FOR TREATMENT OF PANCREATITIS (2025-12-16),

2. 12053467 - Method of treating fibrosis (2024-08-06),

3. 11975041 - Composition comprising CHP (cyclo-his pro) for preventing, improving or treating of bone loss related disease (2024-05-07),

4. 11890317 - Cell-protecting composition containing cyclo histidine-proline as active ingredient (2024-02-06),

5. 11850246 - Method for treatment of cytokine release syndrome (2023-12-26),

6. 11820834 - Polymorphic forms of Cyclo (-His-Pro) and methods of use to treat kidney disease (2023-11-21),

7. 11607441 - Pharmaceutical composition for preventing or treating diabetes, containing zinc salt, cyclo-hispro and antidiabetic drug as active ingredients (2023-03-21),

8. 11547737 - Compositions and methods for treating virus infection (2023-01-10),

9. 11433114 - Composition for cell protection containing cyclo histidine-proline as active ingredient (2022-09-06),

10. 11413270 - Method for the treatment of pancreatitis (2022-08-16),

11. 11273196 - Antithrombotic composition containingand (2022-03-15),

12. 10918693 - Composition for cell protection containing cyclo histidine-proline as active ingredient (2021-02-16),

13. 10792280 - Pharmaceutical composition comprising amodiaquine and anti-diabetes drug as effective ingredient for prevention or treatment of diabetes (2020-10-06),

14. 10683300 - Polymorphic forms of Cyclo (-His-Pro) (2020-06-16),

15. 10004727 - Composition for preventing, alleviating or treating metabolic diseases, containing amodiaquine as active ingredient (2018-06-26),

Company Overview

Novmetapharma Co., Ltd. is a South Korean company specializing in the development and manufacturing of innovative pharmaceutical products. The organization focuses on advanced drug formulations and delivery systems, aiming to enhance therapeutic efficacy and patient compliance. With a commitment to research and development, Novmetapharma explores various therapeutic areas, leveraging cutting-edge technologies to address unmet medical needs. Its strategic location in Seoul positions it within a vibrant ecosystem of healthcare innovation.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

15 Patents

#282 in Seoul

#782 in South Korea

#39,991 in the World

Seoul, South Korea

Novmetapharma Co., Ltd.

Forward Citations = 11

35 inventors:

Heon Jong Lee (7 out of 9 patents)

Hoe Yune Jung (7 out of 10 patents)

Hoe-Yune Jung (5 out of 5 patents)

4. In-Kyu Lee (3 out of 7 patents)

5. Jae-Han Jeon (3 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Novmetapharma Co., Ltd.. Retrieved from https://idiyas.com/company/novmetapharma-company

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…